Hims & Hers Soars 57% After Settling Dispute with Novo Nordisk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Stock Surge: Hims & Hers (HIMS) experienced a remarkable ~57% increase this week, marking its best weekly performance ever, primarily due to settling a months-long dispute with Novo Nordisk (NVO), which is expected to significantly enhance the company's market performance.
- Partnership Resumption: The agreement allows HIMS to sell Novo Nordisk's brand-name weight-loss drugs on its platform, signaling a restoration of relations that is anticipated to provide new revenue streams and strengthen HIMS's position in the competitive health tech market.
- Analyst Upgrades: Multiple analysts upgraded HIMS, including Citi, which raised its rating from Sell to Neutral, citing that the agreement significantly derisks the company's outlook, indicating increased market confidence in HIMS's future development.
- Mixed Market Reactions: While HIMS remains rated as Hold on Wall Street, Seeking Alpha's Quant System rates it as a Strong Sell, reflecting divergent views in the market regarding the company's prospects, necessitating close monitoring of its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 23.840
Low
16.50
Averages
32.95
High
60.00
Current: 23.840
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Soars 57% After Settling Dispute with Novo Nordisk
- Stock Surge: Hims & Hers (HIMS) experienced a remarkable ~57% increase this week, marking its best weekly performance ever, primarily due to settling a months-long dispute with Novo Nordisk (NVO), which is expected to significantly enhance the company's market performance.
- Partnership Resumption: The agreement allows HIMS to sell Novo Nordisk's brand-name weight-loss drugs on its platform, signaling a restoration of relations that is anticipated to provide new revenue streams and strengthen HIMS's position in the competitive health tech market.
- Analyst Upgrades: Multiple analysts upgraded HIMS, including Citi, which raised its rating from Sell to Neutral, citing that the agreement significantly derisks the company's outlook, indicating increased market confidence in HIMS's future development.
- Mixed Market Reactions: While HIMS remains rated as Hold on Wall Street, Seeking Alpha's Quant System rates it as a Strong Sell, reflecting divergent views in the market regarding the company's prospects, necessitating close monitoring of its future performance.
See More
MarketBeat Weekly Recap – March 9 to March 13
Market Resilience Amid Uncertainty: Despite ongoing volatility, stock markets have shown resilience as investors navigate uncertainties related to oil prices and geopolitical conflicts, with economic indicators remaining generally favorable.
Earnings Season Insights: The current earnings season has provided supportive data for a resilient economy, with companies reporting solid earnings, particularly in sectors like energy and technology, which are adapting to market conditions.
Investment Strategies in Volatile Times: Analysts suggest that investors should focus on blue-chip stocks and companies with strong fundamentals, while also considering opportunities in sectors like biotechnology and renewable energy.
Emerging Trends in Mergers and Acquisitions: The market is witnessing significant mergers and acquisitions, particularly in the healthcare and technology sectors, which could reshape industry dynamics and present new investment opportunities.
See More
NASDAQ 100 Pre-Market Update Highlights Active Stocks
- Pre-Market Indicator Rise: The NASDAQ 100 Pre-Market Indicator increased by 108.49 points to 24,642.07, indicating a positive market sentiment that could set the tone for today's trading.
- Active Stock Performance: Haleon plc (HLN) is trading at $10.06, which is 75.07% of its target price of $13.4, reflecting cautious market sentiment regarding its future performance.
- Nokia Price Recovery: Nokia Corporation (NOK) rose by $0.15 to $8.29, currently exceeding its target price of $7.73 by 107.24%, indicating optimistic market expectations for its prospects.
- Circle Internet Group's Positive Outlook: Circle Internet Group, Inc. (CRCL) increased by $3.89 to $118.07, currently surpassing its target price of $98 by 120.48%, with upward revisions in its EPS forecast for fiscal Q3 2026, suggesting improved earnings expectations.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
Hims & Hers Soars 57% After Settling Dispute with Novo Nordisk
- Stock Surge: Hims & Hers (HIMS) experienced a remarkable ~57% increase this week, marking its best weekly performance ever, primarily due to settling a months-long dispute with Novo Nordisk (NVO), which is expected to significantly enhance the company's market performance.
- Partnership Resumption: The agreement allows HIMS to sell Novo Nordisk's brand-name weight-loss drugs on its platform, signaling a restoration of relations that is anticipated to provide new revenue streams and strengthen HIMS's position in the competitive health tech market.
- Analyst Upgrades: Multiple analysts upgraded HIMS, including Citi, which raised its rating from Sell to Neutral, citing that the agreement significantly derisks the company's outlook, indicating increased market confidence in HIMS's future development.
- Mixed Market Reactions: While HIMS remains rated as Hold on Wall Street, Seeking Alpha's Quant System rates it as a Strong Sell, reflecting divergent views in the market regarding the company's prospects, necessitating close monitoring of its future performance.
See More
MarketBeat Weekly Recap – March 9 to March 13
Market Resilience Amid Uncertainty: Despite ongoing volatility, stock markets have shown resilience as investors navigate uncertainties related to oil prices and geopolitical conflicts, with economic indicators remaining generally favorable.
Earnings Season Insights: The current earnings season has provided supportive data for a resilient economy, with companies reporting solid earnings, particularly in sectors like energy and technology, which are adapting to market conditions.
Investment Strategies in Volatile Times: Analysts suggest that investors should focus on blue-chip stocks and companies with strong fundamentals, while also considering opportunities in sectors like biotechnology and renewable energy.
Emerging Trends in Mergers and Acquisitions: The market is witnessing significant mergers and acquisitions, particularly in the healthcare and technology sectors, which could reshape industry dynamics and present new investment opportunities.
See More
NASDAQ 100 Pre-Market Update Highlights Active Stocks
- Pre-Market Indicator Rise: The NASDAQ 100 Pre-Market Indicator increased by 108.49 points to 24,642.07, indicating a positive market sentiment that could set the tone for today's trading.
- Active Stock Performance: Haleon plc (HLN) is trading at $10.06, which is 75.07% of its target price of $13.4, reflecting cautious market sentiment regarding its future performance.
- Nokia Price Recovery: Nokia Corporation (NOK) rose by $0.15 to $8.29, currently exceeding its target price of $7.73 by 107.24%, indicating optimistic market expectations for its prospects.
- Circle Internet Group's Positive Outlook: Circle Internet Group, Inc. (CRCL) increased by $3.89 to $118.07, currently surpassing its target price of $98 by 120.48%, with upward revisions in its EPS forecast for fiscal Q3 2026, suggesting improved earnings expectations.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
